Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade-Reference-Cited by-同舟云学术

Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade

Published:2019-11 Issue:11 Volume:139 Page:2343-2351.e3
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Koopmans Iris,Hendriks Mark A.J.M.,van Ginkel Robert J.,Samplonius Douwe F.,Bremer Edwin,Helfrich Wijnand

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference24 articles.

1. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells;Boyerinas;Cancer Immunol Res,2015

2. Human high molecular weight-melanoma-associated antigen (HMW-MAA):Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, ack-1 and p130cas;Campoli;Nat Cell Biol,1999

3. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab;Fujii;Oncotarget,2016

4. Inhibition of anchorage-independent growth of human melanoma cells by a monoclonal antibody to a chondroitin sulfate proteoglycan;Harper;J Natl Cancer Inst,1983

5. Melanoma-directed activation of apoptosis using a bispecific antibody directed at MCSP and TRAIL receptor-2/death receptor-5;He;J Invest Dermatol,2016

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy of Human Melanoma: Past, Present, Future;Current Medicinal Chemistry;2024-03-06

2. The present and future of bispecific antibodies for cancer therapy;Nature Reviews Drug Discovery;2024-03-06

3. Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR;Journal for ImmunoTherapy of Cancer;2023-09

4. A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics;Frontiers in Immunology;2023-07-25

5. A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer;Cancers;2023-07-17